Zynex Inc ( (ZYXI) ) has released its Q3 earnings. Here is a breakdown of the information Zynex Inc presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zynex, Inc. is a medical technology company that develops, manufactures, and sells non-invasive medical devices for pain management and rehabilitation, as well as monitoring systems for hospital use. In its third-quarter 2025 financial report, Zynex revealed significant financial challenges, including a substantial decline in revenue and a net loss, attributed to payment suspensions and operational setbacks. The company’s net revenue for the quarter was $13.4 million, a sharp decrease from $50 million in the same period the previous year, primarily due to issues with Tricare payments and changes in payer claim practices. Zynex reported a net loss of $42.9 million, exacerbated by a $30.7 million non-cash asset impairment charge. The company is actively exploring strategic alternatives to address its liquidity challenges, including potential capital raising and restructuring strategies, with the assistance of financial advisory firm Province, LLC. Looking ahead, Zynex’s management remains focused on navigating its current financial difficulties and exploring strategic options to stabilize and potentially grow the company in the future.